Influence of proinflamatory macrophages (M-1) on proliferative activity and PPAR-γ expression in neoplastic rat hepatocytes in vitro

• Autorzy: Wojcik M. , Kosior-Korzecka U. , Plewik M. , Bobowiec R.
• Języki publikacji: EN

Abstrakty

EN

We sought to analyse the proliferative activity and PPARγ expression in neoplastic and non-neoplastic rat hepatocytes, exposed to immunologically trained macrophages M1 (Mf-M1). Ten-week-old female Wistar rats were divided into two groups: I - control (n=5) and II neoplstic (n=5). To induce HCC in the neoplastic group, genotoxic diethylnitrosamine (DEN) was administered after a partial hepatectomy (PH). Hepatocytes were isolated by liver perfusion method and the mononuclear blood cells were isolated using Lymphoprep density-gradient centrifugation. After differentiation, blood cells were treated with barley-derived β-glucan (BBG) (10 μg/ml). Adhered heaptocytes and Mf were cultured in 3D Quasi-Vivo System during 24 h. Then, hepatic proliferation and PPAR γ expression were analysed after 72 h and the 1st ,the 2nd and the 3rd week of incubation. The proliferation index of control hepatocytes ranged between 0.41±0.04 – 0.43±0.03 after 72 h and after the 3rd week of incubation respectively. Exposure of these cells to Mf resulted in marked increase of IP after the 1st, the 2nd and the 3rd week of incubation. When hepatocytes were influenced by proinflammatory Mf- M1, their proliferation was maintained at control stage. DEN-obtained hepatocytes, not influenced by macrophages, exhibit enhanced proliferation. When these cells where co-cultured with Mf-M1, marked (P≤0.05) inhibition of cell proliferation was observed. In such condition, a high negative relationship (r= -0.93) between proliferative activity of the hepatocytes and the PPARγ concentration was observed. We conclude that immunologically trained macrophages M1, are capable to activation of PPARγ in rat neoplastic hepatocytes derived from experimentally induced HCC. In turn intensified expression of PPARγ may inhibited proliferation of neoplastic cell in vitro.

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2019
• Tom: 75
• Numer: 09
• Opis fizyczny: p.572-576,fig.,ref.

Twórcy

autor

Wojcik M.

• Chair of Preclinical Veterinary Sciences, Department of Pathophysiology, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Akademicka 12, 20-033 Lublin, Poland

autor

Kosior-Korzecka U.

• Chair of Preclinical Veterinary Sciences, Department of Pathophysiology, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Akademicka 12, 20-033 Lublin, Poland

autor

Plewik M.

• Chair of Preclinical Veterinary Sciences, Department of Pathophysiology, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Akademicka 12, 20-033 Lublin, Poland

autor

Bobowiec R.

• Chair of Preclinical Veterinary Sciences, Department of Pathophysiology, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Akademicka 12, 20-033 Lublin, Poland

Bibliografia

• Biswas S. K., Sica A., Lewis C. E.: Plasticity of macrophage function by distinct molecular mechanisms. J. Immunol. 2008, 180,2011-2017.
• Borbath I., Horsmans Y.: The role of PPARγ in hepatocellular carcinoma. PPAR Research 2008, Article ID 209520.
• Cheung K. F., Zhao J., Hao Y., Li X., Lowe A. W., Cheng A. S., Sung J. J., Jun Yu.: CITED2 is a novel direct effector of peroxisome proliferators-activated receptor γ in suppressing hepatocellular carcinoma cell growth. Cancer 2013, 119, 1217-1226.
• Hsu H. T., Chi C. W.: Emerging role of the peroxisome proliferators-activated receptor-gamma in hepatocellular carcinoma. J. Hepatocell. Carcinoma 2014, 1, 127-135.
• Kang J. S., Wanibuchi H., Morimura K., Gonzales F. J., Fukushima S.: Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis In vivo. Cancer Res. 2007, 67, 11141-11146.
• Koga H. L., Sakisaka S., Harada M., Takagi T., Hanada S., Taniguchi E., Kawaguchi T., Sasatomi K., Kimura R., Hashimoto O., Ueno T., Yano H., Kojiro M., Sata M.: Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 2001, May 33,1087-1097.
• Kosior-Korzecka U., Bobowiec R.: Effect of leptin, insulin and IGF-I on GnRH-induced LH secretion from porcine pituitary cells in vitro. Bull. Vet. Inst. Pulawy 2007, 51, 439-443.
• Lee J., Lim K. T.: SJSZ glycoprotein (38 kDa) modulates macrophage type 1/2-related factors at hepatocarcinogenic stage in N-nitrosodiethylaminetreated Balb/c. Mol. Cell Biochem. 2013, 372, 17-26.
• Lin Y. M. L., Velmurugan B. K., Yeh Y. L., Tu C. C., Ho T. J., Lai T. Y., Tsai C. H., Tsai F. J., Tsai C. H., Huang C. Y.: Activation of estrogen receptors with E2 downregulates peroxisome proliferator-activated receptor gamma in hepatocellular carcinoma. Oncol. Rep. 2013, 30, 3027-3031.
• Mrówka P., Głodkowska E., Młynarczuk-Biały I., Biały Ł., Kuckelkorn U., Nowis D., Makowski M., Legat M., Gołąb J.: Pioglitazone, a PPAR-Gamma ligand, exerts cytostatic/cytotoxic effects againts cancer cells, that do not result from inhibition of proteasome. Acta Biochim. Pol. 2008, 55, 75-84.
• Nojima H., Kuboki S., Shinoda K., Shimizu H., Ohtsuka M., Kato A., Yoshitomi H., Furukawa K., Takayashiki T., Miyazaki M.: Activation of peroxisome proliferators-activated receptor-gamma inhibits tumor growth by negatively regulating nuclear factor-κB activation in parients with hepatocellular carcinoma. J. Hepatobiliary Pancreat. Sci. 2016, 23, 574-584.
• Radwańska P., Kosior-Korzecka U.: Effect of leptin on thyroid-stimulating hormone secretion and nitric oxide release from pituitary cells of ewe lambs in vitro. J. Physiol. Pharmacol 2014, 65, 145-151.
• Saeed S., Quintin J., Kerstens H. H. D., Rao N. A., Aghejenirefah A., Matarese F., Cheng S. C., Ratter J., Berentsen K., van der Ent M., Sharifi N., Janssen-Megens E. M., Huurne M. T., Mandoli A., van Schaik T., Ng A., Burden F., Dowes K., Frontini M., Kumar V., Giammarellos-Bourboulis E. J., Ouwehand W. H., van der Meer J. W. M., Joosten L. A. B., Wijmenga C., Martens J. H. A., Xavier R. J., Logie C., Natea M. G., Stunnenberg H. G.: Epigenetic programming during monocyte to macrophage differentiation and trained innate immunity. Science 2014, 345:1251086, doi:10.1126/science.1251086.
• Shen B., Chu E. S., Zhao G., Man K., Wu C. W., Cheng J. T., Li G., Nie Y., Lo C. M., Teoh N., Farell G. C., Sung J. J., Yu. J.: PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br. J. Cancer 2012, 106, 1486-1494.
• Tada R., Ikeda F., Aoki K., Yoshikawa M., Kato Y., Adachi Y., Tanioka A., Ishibashi K., Tsubaki K., Ohno N.: Barley-derived β-D-glucan induces immunostimulation via a dectin-1-mediated pathway. Immunol. Lett. 2009, 123, 144-148.
• Wójcik M., Kosior-Korzecka U., Bobowiec R.: Cytoprotective action of 17β-oestradiol against iron-induced hepatic oxidative stress in vitro. Bull. Vet. Inst. Pulawy 2010, 54, 259-263.
• Wójcik M., Wessely-Szponder J., Cichoż-Lach H., Celiński K., Bobowiec R.: In Vitro Proinflammatory Polarization of Macrophages Isolated from Hepatocarcinogenic Stage in Humans and Rats. In Vivo 2016, 30, 853-862.
• Wu C., Farell G., Ju J.: Functional role of peroxisome-proliferator-activated receptor γ in hepatocellular carcinoma. J. Gastroen. Hepatol. 2012, 27, 1665-1669.
• Youssef J., Badr M.: Peroxisome proliferators-activated receptors and cancer: challenges and opportunities. Br. J. Pharmacol. 2011, 164, 68-82.
• Yu J., Qiao L., Zimmermann L., Ebert M. P., Zhang H., Lin W., Röcken C., Malfertheiner P., Farrell G. C.: Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006 Jan; 43, 134-143.

Identyfikatory

DOI

10.21521/mw.6220